冠状动脉疾病是最常见的心血管疾病，最初的器官血流中断和随后的器官血流恢复所产生的心肌缺血/再灌注（ischemia reperfusion，I/R）损伤是急性心肌梗死后伴随各种心脏再灌注治疗策略的重要临床难题。虽然血流量的恢复对于氧气的供应是必要的，但再灌注在促进心肌梗死边缘区血流恢复和心肌细胞挽救的同时，也加重了心肌损伤。线粒体功能障碍已被报道为I/R损伤的原因之一，在介导心肌损伤病理生理过程中起着至关重要的作用。主要综述了I/R损伤中线粒体质量控制系统的分子机制以及确立了以线粒体为潜在治疗靶点的可能性。

Coronary artery disease is the most common cardiovascular disease. Myocardial ischemia/reperfusion (I/R) injury caused by the initial interruption of organ blood flow and subsequent restoration of organ blood flow is acute myocardial infarction accompanied by various hearts important clinical problems of reperfusion strategies. Although the recovery of blood flow is necessary for the supply of oxygen, reperfusion promotes the recovery of blood flow in the marginal zone of myocardial infarction and the rescue of myocardial cells, and it also aggravates myocardial damage. Mitochondrial dysfunction has been reported as one of the causes of I/R injury, and it plays a vital role in mediating the pathophysiological process of myocardial injury. The molecular mechanism of the mitochondrial quality control system in I/R injury was briefly reviewed in this paper, in order to establish the possibility of using mitochondria as a potential therapeutic target.

R285

国家自然科学基金资助项目（81973753）；湖南省自然科学基金资助项目（2018JJ2291）；研究生创新课题（2018CX28，2020CX57）